Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock

Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams purchased 1,587,301 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.26 per share, for a total transaction of $1,999,999.26. Following the acquisition, the director owned 32,944,484 shares of the company’s stock, valued at $41,510,049.84. The trade was a 5.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Gregg Williams also recently made the following trade(s):

• On Sunday, March 15th, Gregg Williams purchased 1,575,231 shares of Vivani Medical stock. The stock was purchased at an average price of $1.07 per share, for a total transaction of $1,685,497.17.
• On Tuesday, January 27th, Gregg Williams purchased 1,351,351 shares of Vivani Medical stock. The stock was purchased at an average price of $1.48 per share, for a total transaction of $1,999,999.48.

Vivani Medical Stock Up 2.3%

Vivani Medical stock opened at $1.34 on Friday. The business’s 50-day simple moving average is $1.16 and its 200 day simple moving average is $1.33. The stock has a market cap of $113.43 million, a price-to-earnings ratio of -3.12 and a beta of 2.16. Vivani Medical, Inc. has a 12-month low of $0.92 and a 12-month high of $1.92.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, sell-side analysts expect that Vivani Medical, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on VANI. Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a report on Friday, January 9th. HC Wainwright reduced their target price on Vivani Medical from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Tuesday, March 31st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $3.50.

Hedge Funds Weigh In On Vivani Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in Vivani Medical during the fourth quarter worth about $174,000. Citadel Advisors LLC bought a new position in Vivani Medical during the third quarter worth about $26,000. State Street Corp boosted its holdings in Vivani Medical by 12.5% during the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after buying an additional 16,070 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in Vivani Medical during the fourth quarter worth about $1,127,000. Finally, Geode Capital Management LLC boosted its holdings in Vivani Medical by 29.6% during the fourth quarter. Geode Capital Management LLC now owns 461,652 shares of the company’s stock worth $568,000 after buying an additional 105,398 shares during the last quarter. Institutional investors own 6.78% of the company’s stock.

About Vivani Medical

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.